Análisis de la acción MapLight Therapeutics Inc (MPLT)MPLTMapLight Therapeutics Inc

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009. It operates in the Healthcare sector.

MapLight Therapeutics is not a good buy right now due to its current price of $7.70, which is significantly below analyst targets, including a downgrade to $13 by UBS. The stock has a very low RSI of 17.75, indicating it is oversold, but the negative momentum and substantial losses of 54.08% year-to-date suggest further declines are likely. The main risk is the company's ongoing negative net income, which reached -79,548,000 USD in Q4 2025, indicating financial instability.